Serum protein biomarkers for juvenile dermatomyositis: a pilot study
| Autor: | Gabrielle A. Morgan, Yetrib Hathout, Shefa M. Tawalbeh, Wilfredo Marin, Utkarsh J. Dang, Lauren M. Pachman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty lcsh:Diseases of the musculoskeletal system Disease Gastroenterology 03 medical and health sciences 0302 clinical medicine Rheumatology Internal medicine medicine CXCL10 CXCL11 Juvenile dermatomyositis 030203 arthritis & rheumatology business.industry Serum proteomics SomaScan® medicine.disease Blood proteins Pathophysiology 030104 developmental biology Biomarker (medicine) lcsh:RC925-935 business Pharmacodynamic biomarkers Biomarkers |
| Zdroj: | BMC Rheumatology, Vol 4, Iss 1, Pp 1-15 (2020) |
| ISSN: | 2520-1026 |
| DOI: | 10.1186/s41927-020-00150-7 |
| Popis: | BackgroundBlood accessible biomarkers to assess disease activity and their response to therapies in Juvenile Dermatomyositis (JDM) are urgently needed. This pilot study aims to identify serum protein biomarkers associated with clinical disease activity in untreated JDM and their response to medical therapy.MethodsSomaScan® technology screened JDM patients for 1305 proteins at three points: 1) before start of treatment, 2) while on therapy, and 3) after treatment tapering when patients were clinically inactive. To define disease associated biomarkers, SomaScan® data from untreated JDM patients (n = 8) were compared to SomaScan® data from an independent age-matched healthy control group (n = 12). Longitudinal analysis defined treatment responsive proteins at three time points: untreated (7 samples), treated (7 samples), and clinically inactive (6 samples). To confirm the SomaScan® data, a subset of nine candidate proteins (CXCL11, IL-17B, IL-17D, IL-22, CXCL10, MCP-1, ANGPT2, MIF, IL-23) weretested by ELISA after adding 2 JDM (one untreated, one clinically inactive) serum samples to the same group of JDM girls (8 untreated, 7 treated; 7 clinically inactive) as well as with 17 age, gender, matched healthy controls.ResultsComparison of untreated JDM versus healthy controls identified 202 elevated and 49 decreased serum proteins in JDM patients with an adjustedp-value ConclusionsBlood accessible protein biomarkers reflecting JDM pathophysiology were identified; some of them rebounded after therapy was tapered. Further studies bridging these biomarkers to specific clinical features of JDM are required to confirm the clinical utility of these serum protein biomarkers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink